Liquid Nitrogen Efficiency in Treatment of Giant Cell Tumor of Bone and Prevention of Recurrence

Faur, Cosmin Ioan; Abu-Awwad, Ahmed; Pop, Dániel; Zamfir, C; Gurguş, Daniela; Hoinoiu, Teodora; Motoc, Andrei Gheorghe Marius; Haivas, Carmen; Grigoraş, Mirela Loredana; Folescu, Roxana

doi:10.3390/app10186310

Cited by 9 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cellular membranes are often destroyed by a rapid freezing followed by a delayed thaw. The study looked at the outcomes of cryosurgery with liquid nitrogen,combined with surgical removal and the inclusion of Composite in a limited sample of patients who had histological evidence of bone GCT in various locations (tibia, distal radius, and iliac bone) (8). Giant cell tumour is a locally persistent tumour, and specific portion intralesional excision has a significant chance of recurrence.…”

Section: Discussionmentioning

confidence: 99%

Case Report On Giant Cell Tumour In Distal End Of Radius Left Side Managed With Chemical Cauterization And Bone Grafting

Chhatbar¹,

Deshpande²,

Ahmed³

et al. 2022

Journal of Pharmaceutical Negative Results

View full text Add to dashboard Cite

Giant cell tumour of the bone is a regionally assertive neoplasm that is implemented in practice with elongated curettage andtherapeutic interventions, which would be having lesser risk of recurrence. The skeletal tumour is a single, non malignant, butregionally assertive cancer. In the fully grown skeleton, it most frequently affects the epiphysis region of bones. This is mostcommon in the femur, tibia and lower end of radius. Lower end of radius tumour makes up of about 10 percent of overall bonytumours. The obliteration of osseous and cartilages in the proximal distal radius giant cell tumour cells makes salvaging the forearmjoint morphology and feature difficult. Numerous techniques are given, such as wide excision and allograft rebuilding or ulnacentralized control with wrist fusion. We reveal, outcomes of a lower end of radius tumour adequately treated with chemicalcauterization and bone grafting, to retain forearm and hand degree of freedom and supination with better functional recovery.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report On Giant Cell Tumour In Distal End Of Radius Left Side Managed With Chemical Cauterization And Bone Grafting

Chhatbar¹,

Deshpande²,

Ahmed³

et al. 2022

Journal of Pharmaceutical Negative Results

View full text Add to dashboard Cite

show abstract

“…For instance, WBCs have a minimal role in the diagnosis and severity assessment of head and neck infections [ 13 ]; their significance lies mainly in the evaluation of the patient’s response to therapy. In comparison to odontogenic infections, CRP is a better infection measure than WBC because its level rises more rapidly [ 14 , 15 , 16 ]. CRP is present in minute quantities in healthy persons, increases quickly with infection within a few hours [ 17 ], and then rapidly decreases when the inflammation subsides.…”

Section: Introductionmentioning

confidence: 99%

The Role of C-Reactive Protein and Neutrophil to Lymphocyte Ratio in Predicting the Severity of Odontogenic Infections in Adult Patients

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Odontogenic infections (OI) represent a frequent cause of dental and maxillo-facial interventions, mostly due to late presentations or misdiagnosed complications. It is believed that the intensity of the immunoinflammatory response in OI is the main prognostic factor. Therefore, in this research, it was pursued to determine if the combination of C-reactive protein (CRP) and Neutrophil to Lymphocyte Ratio (NLR) (CRP-NLR) may serve as potential severity predictors in patients with odontogenic infections. Materials and Methods: A retrospective analysis on 108 patients hospitalized for odontogenic infections was conducted at the Department of Maxillofacial Surgery. Depending on the symptom severity scale, patients hospitalized with OI were divided into two equal groups based on infection severity (SS). Results: Patients with severe OI from Group B were associated more frequently with diabetes mellitus and smoking more often than those with a lower severity from Group A. In Group A, abscesses of odontogenic origin accounted for 70.4% of hospitalizations, while in Group B, abscesses and cellulitis were associated in 55.6% of cases (p-value < 0.001). The disease outcomes were more severe in Group B patients, where 22.2% of them developed sepsis, compared to 7.4% of Group A patients (p-value = 0.030). However, there was no significant difference in mortality rates. The SS and systemic immune inflammation index (SII) scores of Group B patients were substantially higher than Group A patients (13.6 vs. 6.1 for the SS score, p-value < 0.001), respectively, 2312.4 vs. 696.3 for the SII score (p-value < 0.001). All biomarker scores, including the CRP-NLR relationship, were considerably higher in Group B patients, with a median score of 341.4 vs. 79.0 in Group B (p-value < 0.001). The CRP-NLR association determined a 7.28-fold increased risk of severe OI. The receiver operating curve (ROC) analysis of CRP-NLR yielded an area under curve (AUC) value of 0.889, with high sensitivity (79.6%) and high specificity (85.1%), for predicting a severe odontogenic infection using biomarkers measured at hospital admission (p-value < 0.001). Conclusions: Therefore, it can be concluded that CRP-NLR is a reliable and affordable biomarker for determining the severity of odontogenic infections that may be included in other prognostic models for dental infections.

show abstract

“…Patients who are eligible for a transplant have the highest survival rate at five years, which reaches about 80% with modern therapy, in contrast to elderly patients non-eligible for transplantation, whose survival rate is only about 20% at five years [ 13 , 14 ]. However, the prognosis continues to be higher compared with other more aggressive hematologic cancers and much higher than some solid tumors, considerably depending on a variety of prognostic factors [ 15 , 16 , 17 ]. Despite aggressive therapy that incorporates almost all available drugs and treatment options [ 18 , 19 , 20 ], strategies to overcome the side effects must be identified in high-risk patients and improve survival in this patient population.…”

Section: Introductionmentioning

confidence: 99%

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients

et al. 2022

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematologic cancer defined by an abnormal development of clonal plasma cells in the bone marrow, releasing vast quantities of immunoglobulins and different proteins. In the majority of patients, MM remains incurable despite decades of medical improvement and a number of treatment breakthroughs. Frontline standard-of-care has little long-term success, with the majority of patients eventually relapsing, although the overall progression-free survival (PFS) has improved significantly in the last ten years. Patients who are eligible for a transplant have the highest PFS rate at 5 years, depending on medication response and other various factors that are yet to be discovered. Therefore, the current study aimed to evaluate the response to VCD (bortezomib, cyclophosphamide, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) used as pretransplant regimens, as well as to compare responses between thalidomide and lenalidomide used as maintenance therapy posttransplant. This retrospective study was performed on a group of 105 hospitalized patients in the Hematology Department of the Timisoara Municipal Emergency Clinical Hospital between January 2016 and December 2021. Data was collected from the paper records of patients with MM who were under-followed. The treatment regimens used as induction therapy were either VCD or VTD if cyclophosphamide was contraindicated. Of the 105 patients, 27 became eligible for bone marrow transplantation. Furthermore, they received maintenance therapy which was based on either lenalidomide with dexamethasone or thalidomide with dexamethasone. Of the 62 patients treated with VTD, 17.7% were in complete remission before stem cell transplantation. Of the 43 patients treated with VCD, 37.2% were in complete remission. The 5-year mean progression-free survival (PFS) in the entire cohort was better in the group treated with the VTD regimen (31.6 vs. 27.2 months). However, in the 27 patients undergoing maintenance after ASCT, the PFS with thalidomide was 35.5 months (95% CI = 27–42), while the PFS rate in those receiving maintenance treatment with lenalidomide was 46.1 months (95% CI = 20–73). VCD proved to be superior to VTD in inducing complete pretransplant responses. Regarding maintenance therapy, patients from the lenalidomide group had superior responses compared with those under thalidomide.

show abstract

Liquid Nitrogen Efficiency in Treatment of Giant Cell Tumor of Bone and Prevention of Recurrence

Cited by 9 publications

References 23 publications

Case Report On Giant Cell Tumour In Distal End Of Radius Left Side Managed With Chemical Cauterization And Bone Grafting

Case Report On Giant Cell Tumour In Distal End Of Radius Left Side Managed With Chemical Cauterization And Bone Grafting

The Role of C-Reactive Protein and Neutrophil to Lymphocyte Ratio in Predicting the Severity of Odontogenic Infections in Adult Patients

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients

Contact Info

Product

Resources

About